FDA 483 - Pfizer Ireland Pharmaceuticals Unlimited Company - November 12, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Pfizer Ireland Pharmaceuticals in Clondalkin, Ireland, revealed two significant observations related to quality system deficiencies. The firm failed to submit required biological product deviation reports for confirmed US complaints of particles in Prevnar and did not thoroughly review unexplained discrepancies, including a test failure and incomplete BPDR information regarding an atypical rubber component in Prevnar. These issues highlight concerns with product quality and regulatory reporting.
- Inspection Date
- November 12, 2019
- Product Type
- Biologics
ID · 67e84118-13d5-491c-b980-4f7516269ab2